Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects

Journal of Nutritional Biochemistry

Volumn 22, Issue 3, 2011, Pages 289-292

  Kim, Young Choon ^a   Cho, Yong Kyun ^a   Lee, Won Young ^a   Kim, Hong Joo ^a   Park, Jung Ho ^a   Park, Dong Il ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a   Park, Se Eun ^a   Rhee, Eun Jung ^a   Park, Cheol Young ^a   Oh, Ki Won ^a   Park, Sung Woo ^a   Kim, Sun Woo ^a   Ryu, Seung Ho ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adipocyte specific fatty acid binding protein; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

ADIPOCYTE SPECIFIC FATTY ACID BINDING PROTEIN; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HOMEOSTASIS MODEL ASSESSMENT INDEX OF INSULIN RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONALCOHOLIC FATTY LIVER; RISK FACTOR;

ADIPOCYTES; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ODDS RATIO; REPUBLIC OF KOREA; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951676435     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.02.007     Document Type: Article

References (23)

1. Tilg H., Hotamisligil G.S. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006, 131:934-945.
2. Czaja M.J. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004, 40:19-22.
3. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27:412-421.
4. Boord J.B., Maeda K., Makowski L., Babaev V.R., Fazio S., Linton M.F., et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004, 110:1492-1498.
5. Furuhashi M., Fucho R., Görgün C.Z., Tuncman G., Cao H., Hotamisligil G.S. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008, 118:2640-2650.
6. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H., et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
7. Tso A.W., Xu A., Sham P.C., Wat N.M., Wang Y., Fong C.H., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
8. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
9. Reinehr T., Stoffel-Wagner B., Roth C.L. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism 2007, 56:1735-1741.
10. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
11. WHO Western Pacific Region, IASO and IOTF: the Asia-Pacific Perspective: redefining obesity and its treatment 2000, Health Communications Australia Pty Limit, Sydney, Australia.
12. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
13. Saverymuttu S.H., Joseph A.E., Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986, 292:13-15.
14. Osawa H., Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996, 24:25-29.
15. Angelico F., Del Ben M., Conti R., Francioso S., Feole K., Fiorello S., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005, 90:1578-1582.
16. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
17. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a non-invasive system that accurately identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
18. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
19. Guha I., Parkes J., Roderick P., Chattopadhay D., Cross R., Harris S., et al. Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology 2007, 47:455-460.
20. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H., Shin J.Y. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in Type 2 diabetic patients. Diabetes Care 2009, 32:147-152.
21. Milner K.L., van der Poorten D., Xu A., Bugianesi E., Kench J.G., Lam K.S., et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009, 49:1926-1934.
22. Joseph A.E., Saverymuttu S.H., al-Sam S., Cook M.G., Maxwell J.D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
23. Needleman L., Kurtz A.B., Rifkin M.D., Cooper H.S., Pasto M.E., Goldberg B.B. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. Am J Roentgenol 1986, 146:1011-1015.